- Alireza Faridar, MD (Houston Methodist and Weill Cornell Medical College) will present data from an open-label, proof-of-concept study in 8 AD patients treated with Low Dose IL-2 (LD IL-2) over a 4 month period that resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE) and no cognitive decline as observed by the AD Assessment Scale–Cognitive Subscale (ADAS-Cog), and the Clinical Dementia Rating-Sum of Boxes scale (CDR-SB);
- It has been recently announced here that a double-blind, placebo-controlled study (funded by the Gates Foundation and Alzheimer’s Association) evaluating safety and tolerability, biological activity, relevant biomarkers, neuroimaging, and efficacy of LD IL-2 in 38 patients with mild-to-moderate AD over 30 weeks is fully enrolled and will release top line data in the first half of 2024;
- Coya’s proprietary investigational LD IL-2 (COYA 301) for subcutaneous administration has been designed to enhance the function of Tregs in vivo and is being developed as a monotherapy for the treatment of AD.
RenovoRx CEO Updates Shareholder Letter
Dear Fellow RenovoRx Shareholders,The first quarter of 2024 marked a significant period in our company's evolution, and we have set the stage for significant milestones in the foreseeable future. Our team is steadfast in
